stockrow
Monday 9 November 2026
Export PYXS’s income statement to Excel — free account
Pyxis Oncology, Inc.
PYXSPyxis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.9 million, down 14.2% from fiscal 2024.
- EPS
- −33.3%
- Free cash flow
- −5.46%
Quarter to June 2026, against a year earlier
1.66
0.05
+3.11%
Follow PYXS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 16 | 14 | — | (14.2%) | — | 3 | 14 | (0.1%) | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 97.06 | 82.77 | 0.00 | +82.8 pt | ||||||
| EBT | — | — | — | (3) | (13) | (76) | (121) | (74) | (79) | (78) | (88) | +74.5% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (492.35) | (564.55) | 0.00 | (564.6) pt | ||||||
| Net income | — | 0 | — | (3) | (13) | (76) | (121) | (74) | (77) | (80) | (89) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.22 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.08) | (12.44) | (8.95) | (3.65) | (1.85) | (1.32) | (1.28) | (1.41) | +58.7% | ||||||
| Cash flow | — | — | — | (0.07) | (9.78) | (4.16) | (2.70) | (1.77) | (0.99) | (1.02) | (1.06) | +58.2% | ||||||
| Capex | — | — | — | 0.00 | (1.44) | (0.06) | (0.19) | (0.17) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.07) | (11.22) | (4.22) | (2.90) | (1.94) | (0.99) | (1.02) | (1.06) | +58.2% | ||||||
| Book value | — | — | — | 0.56 | (15.17) | 30.77 | 4.87 | 3.15 | 2.07 | 0.86 | 0.18 | +7.5% | ||||||
| Shares, m | — | — | — | 34 | 1 | 8 | 33 | 40 | 58 | 62 | 63 | +10.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.76 | 1.34 | 9.29 | 1.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.64 | (0.05) | (1.06) | 0.3 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (2) | (10) | (35) | (89) | (71) | (58) | (64) | (68) | +74.6% | |||||
| Capex | — | — | — | — | (1) | (1) | (6) | (7) | 0 | 0 | 0 | (64.0%) | ||||||
| Free cash flow | — | — | — | (2) | (12) | (36) | (96) | (77) | (58) | (64) | (68) | +74.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 19 | 4 | 260 | 155 | 99 | 115 | 51 | 9 | +17.9% | |||||
| Net debt | — | — | — | (20) | (8) | (276) | (181) | (121) | (128) | (68) | (34) | +23.1% | ||||||
| Shareholders’ equity | — | — | — | 19 | (16) | 261 | 161 | 126 | 121 | 53 | 11 | +18.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (27.99) | (85.64) | (52.37) | (49.13) | (38.32) | (46.74) | (64.03) | (99.62) | (36.0) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,041.19) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 29.94 | 138.54 | (61.85) | (57.19) | (51.51) | (62.75) | (91.43) | (179.10) | (121.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 56 | 75 | 50 | 44 | 56 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.37 | 0.25 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 25 Oct 2026
Pyxis Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ELDN Eledon Pharmaceuticals, Inc. | $211.7M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IKT Inhibikase Therapeutics, Inc. | $209.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −123.23% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARTV Artiva Biotherapeutics, Inc. | $202.9M | — (loss-making) | — (loss-making) | — | n/m | +13.60% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PYXS Pyxis Oncology, Inc. | $198.6M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | |
| PALI Palisade Bio, Inc. | $196.9M | 1.7× | — (loss-making) | +19,900.00% (above 0%: growing) | n/m | −318.44% (below 0%: shrinking) | 100.00% | (2,339.60%) | Compare |
| IFRX InflaRx N.V. | $192.3M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +59.76% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| PRQR ProQR Therapeutics N.V. | $190.5M | — (loss-making) | — (loss-making) | +135.03% (above 0%: growing) | n/m | −1.06% (below 0%: shrinking) | 100.00% | (100.72%) | Compare |
| RNA Atrium Therapeutics, Inc. | $185.8M | — (loss-making) | — (loss-making) | — | n/m | — | 100.00% | (752.93%) | Compare |
| KROS Keros Therapeutics, Inc. | $183.7M | — (loss-making) | — (loss-making) | +120.22% (above 0%: growing) | n/m | +6.87% (above 0%: growing) | 100.00% | 32.04% | Compare |
| Median of peers | $194.6M | — | — | +120.22% | — | −1.06% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 21 October 2026
Ownership
Directors and executive officers, together
10.50%
GordonMD Global Investments LP
16.40%
Entities affiliated with Biotechnology Value Fund LP
9.99%
Entities affiliated with RTW Investments, LP
8.40%
Entities affiliated with OrbiMed
7.20%
Lara Sullivan, M.D.
6.30%
Entities affiliated with Pfizer Inc.
5.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement